| Name: |
DIAZOXIDE(HyperstatR) |
| Classification: |
antihypertensive agent
- relaxes smooth muscle in the peripheral arterioles resulting in decreased blood pressure and increased cardiac output
- can be used to treat hypoglycemia induced by oral hypoglycemic agents (eg. glyburide) as produces a prompt dose-related increase in blood glucose level, due primarily to an inhibition of insulin release from the pancreas and also to an extrapancreatic effect
|
| Dose: |
Bolus doses:
- 1-3 mg/kg q5-15 min to a total of 300 mg; OR
- 50 mg q5 min to a total of 300 mg
|
| Administration: |
- administer rapidly undiluted as IV direct bolus.
- slow infusion of diazoxide may be used in non-emergent situations: 15-30 mg/min over 20-30 minutes
|
| Adverse Effects: |
- increased blood glucose: effect is potentiated in the presence of hypokalemia
- tachycardia
- hypotension
- decreased CO
- myocardial ischemia
- cellulitis/phlebitis: may result from extravasation as solution is highly alkaline
|
| Drug Interactions: |
- diazoxide + diuretics = increased hyperglycemic and hypotensive effect
- diazoxide + corticosteroids = increased hyperglycemic effect
|
| Monitoring Therapy: |
- HR
- arterial blood pressure
- blood glucose
- ECG
- electrolytes
|
| CCTC Protocol: |
- May be administered IV direct by an approved nurse in CCTC providing the drug administration rate does not exceed 50mg/10 seconds and total dose does not exceed 300mg.
|
Print
Handheld
Contrast
